Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nrx Pharmaceuticals Inc (NQ: NRXP )

2.370 +0.110 (+4.87%)
Streaming Delayed Price Updated: 10:11 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,066
Open 2.270
Bid (Size) 2.260 (1)
Ask (Size) 2.340 (1)
Prev. Close 2.260
Today's Range 2.261 - 2.379
52wk Range 1.900 - 7.333
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Exposures Product Safety
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News

Performance

YTD
-52.51%
-52.51%
1 Month
-8.14%
-8.14%
3 Month
-8.14%
-8.14%
6 Month
-36.80%
-36.80%
1 Year
-39.25%
-39.25%

More News

Read More
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024
Via InvestorPlace
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
Via ACCESSWIRE
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Gold Down Over 2%; 3M Profit Beats Expectations
Via Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
Via Benzinga
InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M
Via Investor Brand Network
Exposures Product Safety
Nasdaq Down 0.5%; Lithium Americas Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Via InvestorPlace
Why Is AGBA Group (AGBA) Stock Up 149% Today?
Via InvestorPlace
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.